5 sources covering
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Who's covering it
First reported by CNBC at · 5 outlets in all
- CNNFDA warns weight loss drugs may increase risk of sudden vision loss
- MarketWatchThe FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision lossSeveral medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
- APFDA adds rare vision-loss warning to popular GLP-1 drugs
- Ars TechnicaFDA warns GLP-1 drugs may pose risk of rare condition that causes vision lossThe risk appears small and data is mixed, but FDA wants patients to be aware.
- CNBCFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundThe agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.